JP2023523323A5 - - Google Patents
Info
- Publication number
- JP2023523323A5 JP2023523323A5 JP2022565600A JP2022565600A JP2023523323A5 JP 2023523323 A5 JP2023523323 A5 JP 2023523323A5 JP 2022565600 A JP2022565600 A JP 2022565600A JP 2022565600 A JP2022565600 A JP 2022565600A JP 2023523323 A5 JP2023523323 A5 JP 2023523323A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- mek inhibitor
- kras
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063015883P | 2020-04-27 | 2020-04-27 | |
| US63/015,883 | 2020-04-27 | ||
| PCT/US2021/029435 WO2021222278A1 (en) | 2020-04-27 | 2021-04-27 | Methods of treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523323A JP2023523323A (ja) | 2023-06-02 |
| JP2023523323A5 true JP2023523323A5 (enExample) | 2024-05-10 |
Family
ID=78332185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565600A Pending JP2023523323A (ja) | 2020-04-27 | 2021-04-27 | 異常な細胞成長を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230201198A1 (enExample) |
| EP (1) | EP4142882A4 (enExample) |
| JP (1) | JP2023523323A (enExample) |
| KR (1) | KR20230011277A (enExample) |
| CN (1) | CN115916346A (enExample) |
| AU (1) | AU2021263742A1 (enExample) |
| BR (1) | BR112022021657A2 (enExample) |
| CA (1) | CA3175481A1 (enExample) |
| IL (1) | IL297650A (enExample) |
| MX (1) | MX2022013430A (enExample) |
| WO (1) | WO2021222278A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| WO2023138630A1 (zh) * | 2022-01-21 | 2023-07-27 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| WO2023147297A2 (en) * | 2022-01-25 | 2023-08-03 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| CN118574825A (zh) * | 2022-02-28 | 2024-08-30 | 微境生物医药科技(上海)有限公司 | 作为fak抑制剂的化合物及其用途 |
| CN118973580A (zh) * | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| EP4531846A4 (en) * | 2022-06-03 | 2026-05-27 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2025010293A2 (en) * | 2023-07-03 | 2025-01-09 | Immuneering Corporation | Mek immune oncology inhibitor pharmaceutical compositions |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025261499A1 (zh) * | 2024-06-20 | 2025-12-26 | 上海科州药物股份有限公司 | 蛋白激酶Mek抑制剂苯并噻唑的颗粒药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102859355B (zh) * | 2009-08-24 | 2015-10-07 | 基因泰克公司 | 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性 |
| US20110118298A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2012061683A2 (en) * | 2010-11-05 | 2012-05-10 | Glaxosmithkline Llc | Methods for treating cancer |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| AU2016258192B2 (en) * | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| KR102811888B1 (ko) * | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| KR20220134522A (ko) * | 2019-11-27 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 디아릴 매크로시클릭 화합물을 수반하는 병용 요법 |
-
2021
- 2021-04-27 AU AU2021263742A patent/AU2021263742A1/en active Pending
- 2021-04-27 IL IL297650A patent/IL297650A/en unknown
- 2021-04-27 WO PCT/US2021/029435 patent/WO2021222278A1/en not_active Ceased
- 2021-04-27 EP EP21797285.0A patent/EP4142882A4/en active Pending
- 2021-04-27 KR KR1020227037020A patent/KR20230011277A/ko not_active Ceased
- 2021-04-27 US US17/921,509 patent/US20230201198A1/en active Pending
- 2021-04-27 BR BR112022021657A patent/BR112022021657A2/pt unknown
- 2021-04-27 MX MX2022013430A patent/MX2022013430A/es unknown
- 2021-04-27 CA CA3175481A patent/CA3175481A1/en active Pending
- 2021-04-27 CN CN202180028579.0A patent/CN115916346A/zh active Pending
- 2021-04-27 JP JP2022565600A patent/JP2023523323A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513015A5 (enExample) | ||
| JP2019532051A5 (enExample) | ||
| Aoyama et al. | Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer | |
| Ducreux et al. | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study) | |
| JPWO2023140329A5 (enExample) | ||
| JP2022519375A5 (enExample) | ||
| Vadell et al. | Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia | |
| JP2020514311A5 (enExample) | ||
| JP2024527109A5 (enExample) | ||
| Ji et al. | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis | |
| Kodera | Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan | |
| Kobayashi et al. | Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure | |
| JP2024528705A5 (enExample) | ||
| Gruber et al. | Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model | |
| Tanaka et al. | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma | |
| Ulusakarya et al. | Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma | |
| Ilson | Immunotherapy in esophagogastric cancer | |
| Zhang et al. | Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational study | |
| El Din | Sunitinib 4/2 Versus 2/1 schedule for patients with metastatic renal cell carcinoma: tertiary care hospital experience | |
| Deng et al. | Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report | |
| Toyoda et al. | Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004) | |
| Zhang et al. | Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report | |
| Leng et al. | Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting | |
| Hampton | Cancer Drug Trials Show Modest Benefit | |
| Lim et al. | Gemcitabine and erlotinib with or without oxaliplatin in previously untreated advanced pancreatic cancer: A randomized phase II trial |